Purchase this article with an account.
Kenichiro Mori, Keijiro Ishikawa, Yuki Kubo, Yoshiyuki Kobayashi, Takahito Nakama, Shintaro Nakao, Shigeo Yoshida, Koh-hei Sonoda; Metamorphopsia changes after anti-VEGF therapy in branch retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4051.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We performed a retrospective, observational clinical studyto study changes in amount of metamorphopsia after anti-VEGF therapy for macular edema (ME) in branch retinal vein occlusion (BRVO).
This study enrolled 29 eyes of 29 patients with ME secondary to BRVO. Those patients were treated with intravitreal injections of anti-VEGF agents using a TAE regimen for at least 18 months at Kyushu University Hospital. We evaluated log MAR visual acuity, central macular thickness(CMT), ME recurrence and amount of metamorphopsia that was quantified by M-CHARTS.
Log MAR visual acuity and CMT significantly improved from 0.35±0.29 and 468±106μm at baseline to 0.06±0.18 and 289±82μm at 18 months (P<0.0001). The average vertical M-CHARTS score significantly decreased from 0.75±0.73 at baseline to 0.59±0.52 and 0.54±0.45 at 1 and 6 months and the horizontal M-CHARTS score significantly decreased from 0.50±0.45 at baseline to 0.35±0.37 at 6 months (p<0.05). However, neither vertical nor horizontal M-CHARTS significantly changed at 18 months (vertical: 0.56±0.58(P=0.10) and horizontal: 0.37±0.44(P=0.12)).ME recurrence occurred in 22 eyes during the follow-up period (75.9%). The number of ME recurrence was significantly smaller in the eyes with maintained or improved vertical M-CHARTS than those with worsened vertical M-CHARTS at 18 months (p<0.05).
Anti-VEGF therapy using TAE regimen may not improve metamorphopsia in BRVO-ME after long-term follow-up.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only